Multiple myeloma

Marc S Raab, Klaus Podar, Iris Breitkreutz, Paul G Richardson, Kenneth C Anderson

Research output: Journal article (peer-reviewed)Review article

672 Citations (Scopus)

Abstract

Multiple myeloma is characterised by clonal proliferation of malignant plasma cells, and mounting evidence indicates that the bone marrow microenvironment of tumour cells has a pivotal role in myeloma pathogenesis. This knowledge has already expanded treatment options for patients with multiple myeloma. Prototypic drugs thalidomide, bortezomib, and lenalidomide have each been approved for the treatment of this disease by targeting both multiple myeloma cells and the bone marrow microenvironment. Although benefit was first shown in relapsed and refractory disease, improved overall response, duration of response, and progression-free and overall survival can be achieved when these drugs are part of first-line regimens. This treatment framework promises to improve outcome not only for patients with multiple myeloma, but also with other haematological malignancies and solid tumours.

Original languageEnglish
Pages (from-to)324-339
Number of pages16
JournalThe Lancet
Volume374
Issue number9686
DOIs
Publication statusPublished - 25 Jul 2009
Externally publishedYes

Keywords

  • Antineoplastic Agents/therapeutic use
  • Boronic Acids/therapeutic use
  • Bortezomib
  • Clinical Trials as Topic
  • Combined Modality Therapy
  • Genetic Predisposition to Disease/genetics
  • Humans
  • Lenalidomide
  • Melphalan/therapeutic use
  • Multiple Myeloma/diagnosis
  • Neoplasm Staging
  • Protease Inhibitors/therapeutic use
  • Pyrazines/therapeutic use
  • Remission Induction
  • Stem Cell Transplantation
  • Survival Rate
  • Thalidomide/analogs & derivatives
  • Treatment Outcome

Fingerprint

Dive into the research topics of 'Multiple myeloma'. Together they form a unique fingerprint.

Cite this